Safety Study Using Weekly Infusions of BB-10901 in Patients With Small Cell Lung Cancer

Completed · Phase 1/Phase 2

Conditions studied: Small Cell Lung Cancer

In brief

This study was a Phase I/II trial primarily focused on efficacy of BB-10901 in relapsed small cell lung cancer and other solid tumors.

Key facts

Study ID

NCT00065429

Run by

ImmunoGen, Inc.

People needed

64

Starts

2003-04-01

Expected to finish

2008-12-01

Last updated by the study team

2012-07-18

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

• Rocky Mountain Cancer Centers — Denver, Colorado, United States
• Cancer Center of Florida — Ocoee, Florida, United States
• Baystate Medical Center — Springfield, Massachusetts, United States
• New York Oncology Hematology — Albany, New York, United States
• The Ohio State University — Colombus, Ohio, United States
• Greater Dayton Cancer Center — Kettering, Ohio, United States
• Cancer Centers of the Carolinas — Greenville, South Carolina, United States
• MD Anderson Cancer Center — Houston, Texas, United States
• Tyler Cancer Center — Tyler, Texas, United States
• Virginia Oncology Associates — Norfolk, Virginia, United States
• Northwest Cancer Specialists — Vancouver, Washington, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.